INKT
MiNK Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.60
−1.76%Nov 2, 2026, 21:35 UTC
MiNK Therapeutics, Inc. announced that it will report its third-quarter 2026 results.
Source:Sep 30, 2026, 11:57 UTC
MiNK Therapeutics was selected to provide its agenT-797 iNKT cell therapy platform for the ARPA-H-funded BoSS program, which aims to move living medicines from cryogenic storage toward room temperature.
Source:Aug 13, 2026, 11:30 UTC
MiNK Therapeutics reported its financial results for the second quarter ended June 30, 2026.